Biotech Values

[alertmeipp]

some of u guys think the share price (back to pre-approval level) is indicating that TEVA approval is imminent and that the market doesn't give much value to the sole generic because it's a couple quarters wonder.

And yet at the same time those individuals think the the market will overshoot to the downside when the TEVA "much anticipated"* actually come.

You don't need a high-school degree to see that even with multiple generics scenarios, it's still an valuable asset.

Please apply some common sense here. :)

*I see good chances that TEVA will give up on it without a PR